Results 261 to 270 of about 58,085 (295)

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Nature Medicine, 2022
Adriaan A Voors, Christiane Angermann Angermann, John R Teerlink   +2 more
exaly  

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

Hippokratia, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors are effective glucose-lowering agents that do not increase body weight and are associated with a low risk for hypoglycemia. Also, they appear to exert beneficial effects on other established cardiovascular risk factors, including dyslipidemia and hypertension.
M, Papagianni, K, Tziomalos
openaire   +1 more source

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Nature Medicine, 2021
Barry A Borlaug, Dalane W Kitzman, Sanjiv J Shah   +2 more
exaly  

Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase‐4 inhibitor or a sulphonylurea: Results from the OsMed Health‐DB registry

Diabetes, obesity and metabolism, 2017
G. Fadini, S. Saragoni, P. Russo, L. Degli Esposti, S. Vigili de Kreutzenberg, M. Melazzini, A. Avogaro   +6 more
semanticscholar   +1 more source

Dipeptidyl-peptidase-4-inhibitors/insulin degludec

Reactions Weekly, 2022
openaire   +1 more source

Efficacy and safety of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24‐week, multicentre, randomized, double‐blind, placebo‐controlled study (TROICA study)

Diabetes, obesity and metabolism, 2017
C. H. Ahn, K. Han, J. Yu, J. Nam, K. Ahn, T. Oh, H. Lee, D. Lee, Jaetaek Kim, C. Chung, T. Park, B. Kim, Seok Won Park, H. Park, K. Lee, Sang-Wook Kim, Jeong Hyun Park, Kwan Pyo Ko, C. Kim, Hyunjin Lee, H. Jang, K. Park   +21 more
semanticscholar   +1 more source

Inhibitors of Dipeptidyl Peptidase 4

2005
Stephen L. Gwaltney, Jeffrey A. Stafford
openaire   +1 more source

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians, 2018
Clement Chung
exaly